দেশ: কানাডা
ভাষা: ইংরেজি
সূত্র: Health Canada
PSEUDOEPHEDRINE SULFATE; LORATADINE
BAYER INC
R01BA52
PSEUDOEPHEDRINE, COMBINATIONS
120MG; 5MG
TABLET (IMMEDIATE AND EXTENDED RELEASE)
PSEUDOEPHEDRINE SULFATE 120MG; LORATADINE 5MG
ORAL
10/20/30
OTC
SECOND GENERATION ANTIHISTAMINES
Active ingredient group (AIG) number: 0245861002; AHFS:
APPROVED
2014-12-08
_<_ _CLARITIN_ _®_ _ ALLERGY + SINUS>_ _ _ _ সম্পূর্ণ নথি পড়ুন_ _ _ _Page 1 of 33_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION CLARITIN® ALLERGY + SINUS Loratadine and Pseudoephedrine Sulfate Modified-Release Tablets, Professed Standard 5 mg Loratadine and 120 mg Pseudoephedrine Sulfate; Oral CLARITIN® ALLERGY + SINUS EXTRA STRENGTH Loratadine and Pseudoephedrine Sulfate Modified-Release Tablets, Professed Standard 10 mg Loratadine and 240 mg Pseudoephedrine Sulfate; Oral Histamine H1 receptor antagonist/Sympathomimetic amine Bayer Inc. 2920 Matheson Blvd. E Mississauga, ON L4W 5R6 Date of Initial Authorization: Claritin® Allergy + Sinus: 2-Mar-1993 Claritin® Allergy +Sinus Extra Strength: 4-Dec-2004 Date of Revision: NOV-01-2022 Submission Control Number: 265671 ® TM see www.bayer.ca/tm-mc _ _ _< CLARITIN_ _®_ _ ALLERGY + SINUS> _ _ _ _ _ _Page 2 of 33 _ TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . TABLE OF CONTENTS ........................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................. 4 1. INDICATIONS................................................................................................................ 4 1.1 Pediatrics .................................................................................................................. 4 1.2 Geriatrics................................................................................................................... 4 2. CONTRAINDICATIONS .................................................................................................. 4 4. DOSAGE AND ADMI